teaser
Commenting on the announcement earlier today that the first patient has been treated ReNeuron’s stem cell therapy for stroke clinical trial Nigel Gaymond, BioIndustry Association (BIA) Chief Executive, said: “The commencement of the UK’s first stem cell trial is a ground-breaking achievement and highlights the UK’s world-leading expertise in stem cell research.
“It is also of real significance that the trial is being conducted within the NHS, one of the UK’s unique assets. We wish the patients in this trial and ReNeuron every success.”
